Maxwell Wealth Strategies Inc. Trims Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Maxwell Wealth Strategies Inc. lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 38.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,135 shares of the medical research company's stock after selling 4,435 shares during the quarter. Maxwell Wealth Strategies Inc.'s holdings in IQVIA were worth $1,402,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. Smith Group Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter worth $1,616,000. Nordea Investment Management AB lifted its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. bought a new position in shares of IQVIA during the 4th quarter valued at approximately $941,000. Fifth Third Bancorp increased its holdings in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Finally, Graphene Investments SAS raised its stake in IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock worth $2,948,000 after acquiring an additional 2,700 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Robert W. Baird reduced their price objective on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, January 21st. BTIG Research lowered IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Barclays restated an "equal weight" rating and issued a $170.00 price objective (down from $235.00) on shares of IQVIA in a research report on Thursday. Truist Financial cut their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday. Finally, Mizuho dropped their price target on IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $241.50.

IQVIA Trading Up 2.4 %

Shares of NYSE IQV traded up $3.45 during trading hours on Monday, hitting $149.00. 850,980 shares of the company traded hands, compared to its average volume of 1,382,233. The company's 50 day moving average price is $182.32 and its 200 day moving average price is $199.38. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The stock has a market capitalization of $26.27 billion, a price-to-earnings ratio of 19.87, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.